Lower-dose valganciclovir for the prevention of cytomegalovirus after solid organ transplantation: an important tradeoff.
Department of Medicine, Section of Infectious Diseases, Baylor College of Medicine, Houston, Texas, USA.
R J
RJ
Arasaratnam
D064591:Allografts / Q000821:virology*; D000998:Antiviral Agents / Q000008:administration & dosage*; D003586:Cytomegalovirus Infections / Q000517:prevention & control*; D005260:Female; D015774:Ganciclovir / Q000031:analogs & derivatives*; D006084:Graft Rejection / Q000517:prevention & control*; D006801:Humans; D007166:Immunosuppressive Agents / Q000009:adverse effects*; D007676:Kidney Failure, Chronic / Q000601:surgery*; D016030:Kidney Transplantation; D008297:Male
D000998:Antiviral Agents; D007166:Immunosuppressive Agents; D015774:Ganciclovir
cytomegalovirus infection; valganciclovir